Hobart Private Capital’s Gilead Sciences GILD Stock Holding History

Hobart Private Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,976	Closed	-$274K	–	106
2021 Q2	$274K	Sell	3,976 -265	-6%	-$17.7K	0.11%	107
2021 Q1	$274K	Sell	4,241 -2,929	-41%	-$189K	0.11%	113
2020 Q4	$418K	Sell	7,170 -8,328	-54%	-$503K	0.18%	99
2020 Q3	$979K	Buy	15,498 +10,334	+200%	+$717K	0.51%	31
2020 Q2	$397K	Sell	5,164 -16,010	-76%	-$1.23M	0.22%	110
2020 Q1	$1.58M	Buy	21,174 +1,962	+10%	+$136K	1.09%	21
2019 Q4	$1.25M	Buy	19,212 +1,050	+6%	+$68.4K	0.76%	34
2019 Q3	$1.15M	Buy	+18,162	New	+$1.19M	0.78%	37

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Hobart Private Capital's GILD Position: Q3 2021 in Review

Hobart Private Capital sold out of Gilead Sciences (GILD) in Q3 2021, closing a stake of 3,976 shares — an estimated $274K sold.

Hobart Private Capital first reported a position in GILD in Q3 2019 and held it in 8 quarters. The position peaked at $1.58M in Q1 2020. 1,564 funds tracked by Wall St. Rank hold GILD as of Q3 2021.

Hobart Private Capital reported no remaining Gilead Sciences position as of Q3 2021 after selling out during the quarter.
Hobart Private Capital sold 3,976 Gilead Sciences shares in Q3 2021, an estimated $274K.
Hobart Private Capital first reported a position in Gilead Sciences in Q3 2019 and held it in 8 quarters.
Hobart Private Capital's Gilead Sciences position peaked at $1.58M in Q1 2020.
1,564 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2021.

Based on Hobart Private Capital's 13F filing for Q3 2021, filed 11 Mar 2024.